Parvovirus B19 infection in HIV-infected patients

Cover Page

Cite item

Full Text

Abstract

Here we provide a review of the literature and a description of our own clinical case. The patient was a 32-year-old woman who had been infected with HIV for 6 years without antiretroviral therapy. The test results showed CD4 87 cells/μl, viral load 3750 copies/ml. Normochromic normocytic anemia and reticulocytopenia developed soon. In the myelogram, all erythroblasts were 0.5%. The viral load of parvovirus B19 DNA according to PCR was more than 9 million IU/ml. Pure red cell aplasia associated with parvovirus B19 was diagnosed. We started antiretroviral therapy with efavirenz, lamevudine and tenofovir. In addition to blood transfusions, we administered intravenous donor immunoglobulin with a dose increase from 5000 mg to 20 000 mg per day. After discontinuing of intravenous immunoglobulins, the laboratory test results were stable over the next 5 months: hemoglobin was more than 115 g/L, reticulocytes – more than 3%, in the myelogram all erythroblasts were 21%. However, the elimination of parvovirus B19 wasn’t achieved. The maximum decrease in viral load for parvovirus B19 was down to 720 IU/ml. A typical feature of the case was the lack of pure red cell aplasia of the bone marrow with the existing viral load of parvovirus B19. HIV infection progressed: 44 cells/μl, viral load – not determined. The case ended lethally.

About the authors

A. A. Petrenko

Loginov Moscow Clinical Scientific Center

Author for correspondence.
Email: petrenkoandrei13@gmail.com
ORCID iD: 0000-0001-8461-5421

клин. ординатор 2-го курса по специальности «Гематология» ГБУЗ «МКНЦ им. А.С. Логинова»

Russian Federation, Moscow

G. A. Dudina

Loginov Moscow Clinical Scientific Center

Email: petrenkoandrei13@gmail.com
ORCID iD: 0000-0001-9673-1067

д.м.н., зав. гематологическим отд-нием ГБУЗ «МКНЦ им. А.С. Логинова»

Russian Federation, Moscow

N. V. Kremneva

Loginov Moscow Clinical Scientific Center

Email: petrenkoandrei13@gmail.com

врач-гематолог гематологического отд-ния ГБУЗ «МКНЦ им. А.С. Логинова»

Russian Federation, Moscow

A. V. Pivnik

Loginov Moscow Clinical Scientific Center; People’s Friendship University of Russia

Email: petrenkoandrei13@gmail.com

д.м.н, проф. каф. госпитальной терапии с курсами эндокринологии, гематологии и клинической лабораторной диагностики ФГАОУ ВО РУДН, рук. отд. онкогематологии и вторичных иммунодефицитных заболеваний ГБУЗ «МКНЦ им. А.С. Логинова»

Russian Federation, Moscow

References

  1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;1(7898):72-3. doi: 10.1016/s0140-6736(75)91074-0
  2. Landry ML. Parvovirus B19. Microbiol Spectr. 2016;4(3):10.1128/microbiolspec.DMIH2-0008-2015. doi: 10.1128/microbiolspec.DMIH2-0008-2015
  3. Lavrentyeva IN, Antipova AY. Human parvovirus В19: virus characteristics, distribution and diagnostics of parvovirus infection. Russian Journal of Infection and Immunity. 2013;3(4):311-22. doi: 10.15789/2220-7619-2013-4-311-322
  4. Brown KE, Young NS, Liu JM. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol. 1994;16:1-31. doi: 10.1016/1040-8428(94)90040-x
  5. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15(3):485-505. doi: 10.1128/cmr.15.3.485-505.2002
  6. Antipova AY, Nikishov ON, Khamitova IV, et al. A screening research of plasma blood donors for markers parvovirus infection. Russian Journal of Infection and Immunity. 2015;5(2):171-4. doi: 10.15789/2220-7619-2015-2-171-174
  7. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science. 1993;262:114-7.
  8. Young N. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin HematoI. 1988;25:159-72.
  9. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). NEJM. 1994;330:1192-6. doi: 10.1056/NEJM199404283301704
  10. Koduri PR. Novel cytomorphology of the giant proerythroblasts of parvovirus B19 infection. Am J Hematol. 1998;58(2):95-9. doi: 10.1002/(sici)1096-8652(199806)58:2<95::aid-ajh1>3.0.co;2-v
  11. Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care STDS. 2000;14(1):7-11. doi: 10.1089/108729100318082
  12. Nikishov ON, Kuzin AA, Antipova AY, Lavrent’eva IN. Parvovirus infection – contemporary issues in epidemiology and clinical medicine. Epidemiology and Vaccinal Prevention. 2015;14(4):29-35. doi: 10.31631/2073-3046-2015-14-4-29-35
  13. Van Elsacker-Neile AM, Kroon FP, van der Ende ME, et al. Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23(6):1255-60. doi: 10.1093/clinids/23.6.1255
  14. Young NS, Brown KE. Mechanisms of disease parvovirus B19. N Engl J Med. 2004;350:586-97.
  15. Fuller A, Moaven L, Spelman D, et al. Parvovirus B19 in HIV infection: a treatable cause of anemia. Pathology. 1996;28(3):277-80. doi: 10.1080/00313029600169154
  16. Azevedo KM, Setúbal S, Camacho LA, et al. Seroepidemiological study of human parvovirus B19 among human immunodeficiency virus-infected patients in a medium-sized city in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz. 2009;104(6):901-4. doi: 10.1590/s0074-02762009000600014
  17. Setúbal S, Jorge-Pereira MC, de Sant’Anna AL, et al. Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS. Rev Soc Bras Med Trop. 2003;36(2):299-302. doi: 10.1590/s0037-86822003000200014
  18. Slavov SN, Kashima S, Pinto AC, Covas DT. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol. 2011;62(3):247-62. doi: 10.1111/j.1574-695X.2011.00819.x
  19. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune-or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev. 2005;4(5):264-9. doi: 10.1016/j.autrev.2004.10.004
  20. Ferry T, Hirschel B, Dang T, et al. Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. Clin Infect Dis. 2010;50(1):115-8. doi: 10.1086/649004
  21. Bremner JA, Cohen BJ. Parvovirus B19 as a cause of anemia in human immunodeficiency virus-infected patients. J Infect Dis. 1994;169(4):938-40. doi: 10.1093/infdis/169.4.938a
  22. Gyllensten K, Sönnerborg A, Jorup-Rönström C, et al. Parvovirus B19 infection in HIV-1 infected patients with anemia. Infection. 1994;22(5):356-8. doi: 10.1007/bf01715548
  23. Chernak E, Dubin G, Henry D, et al. Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis. 1995;20(1):170-3. doi: 10.1093/clinids/20.1.170
  24. Vernazza PL, Pfister LA, Siegl G, Cassinotti P. High seroprevalence of parvovirus B19 among patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;22(1):198-9. doi: 10.1093/clinids/22.1.198-a
  25. Azevedo KM, Setúbal S, Camacho LA, et al. Parvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patients. Mem Inst Oswaldo Cruz. 2012;107(3):356-61. doi: 10.1590/s0074-02762012000300010
  26. Mylonakis E, Dickinson BP, Mileno MD, et al. Persistent parvovirus B19 related anemia of seven years’ duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy. Am J Hematol. 1999;60(2):164-6. doi: 10.1002/(sici)1096-8652(199902)60:2<164::aid-ajh16>3.0.co;2-4
  27. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113(12):926-33. doi: 10.7326/0003-4819-113-12-926
  28. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-97. doi: 10.1056/NEJMra030840
  29. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin – a report of eight patients. Am J Hematol. 1999;61(1):16-20. doi: 10.1002/(sici)1096-8652(199905)61:1<16::aid-ajh4>3.0.co;2-y

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies